<DOC>
	<DOCNO>NCT00903747</DOCNO>
	<brief_summary>This 2-arm , parallel-group active- placebo-controlled , double-blind randomise study , stratify gender hybrid crossover group design , compare treatment prucalopride 2 mg/day ( intend therapeutic dose ) prucalopride 10 mg/day ( supratherapeutic dose ) placebo . A single oral dose 400 mg moxifloxacin include positive control term effect cardiac repolarisation . Study hypothesis : Treatment therapeutic ( 2 mg ) supratherapeutic ( 10 mg ) dose prucalopride healthy male female volunteer increase QTc interval compare placebo .</brief_summary>
	<brief_title>Thorough Corrected QT Interval ( QTc ) Study To Evaluate Possible Effects Prucalopride ECG Parameters</brief_title>
	<detailed_description>A total number 120 healthy subject ( approximate 1:1 female : male ratio ) plan randomise . Day 1 : baseline ECG profile . Day 1 : Group 1 receive prucalopride , Group 2a receive moxifloxacin , Group 2b receive placebo . On Day 5 ( steady-state level reach ) , full ECG assessment day perform , enable comparison prucalopride 2 mg placebo . Subsequently , number tablet escalate group ( blind ) 1 tablet day 5 tablet . On Day 13 ( steady state supratherapeutic dose level 10 mg prucalopride ) another ECG assessment day perform , enable comparison prucalopride 10 mg placebo . Group 2b receive single dose moxifloxacin Day 15 . All subject discharge Day 16 . Subjects remain CRU throughout treatment period . All subject return follow-up visit Day 30 ( ± 1 week ) ( approximately 14 day last dose ) .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Main 1 . Healthy volunteer age 18 50 year . 2 . Body mass index ( BMI ) 18 30 kg/m2 . 3 . Female subject must : childbearing potential negative serum βhuman chorionic gonadotropin ( βHCG ) test screening , willing able use medically acceptable double barrier method birth control , throughout whole study ; postmenopausal ; receive surgical sterilisation least 6 month screen ; AND female must receive hormone replacement therapy ( HRT ) . Main exclusion Criteria : 1 . Abnormal QTcF and/or heart rate/blood pressure value baseline . 2 . Subjects ECG abnormality may interfere accurate assessment QT interval . 3 . Subjects know cardiovascular disorder . 4 . Subjects know clinically significant arrhythmia . 5 . Subjects risk factor e.g. , Torsades de Pointes . 6 . Subjects clinically relevant , abnormal serum electrolytes complete blood count ( CBC ) screening . 7 . Female subject lactate pregnant . 8 . Subjects suffer significant medical condition . 9 . Subjects know allergy sensitivity moxifloxacin , prucalopride . 10 . Subjects positive screen test hepatitis B , hepatitis C , HIV screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>Prucalopride</keyword>
	<keyword>safety study</keyword>
</DOC>